降钙素输送系统研究进展

Salmon Calcitonin (sCT), a small, 32-amino-acid peptide, is very effective for the treatment of osteoporosis, especially for post menopause. SCT is a powerful inhibitor of osteoclast activity that exerts a rapid, transient, and reversible inhibition of bone reabsorption. However, the therapeutic use of exogenously administered sCT is severely hampered by its rapid elimination from the body and short half-life (only about 43 min), which in combination contribute to its poor and variable systemic bioavailability. In addition, sCT injection can cause nausea, abdominal pain, hand swelling and urticaria on the injection sites. The only non-injection formulation, nasal calcitonin spray, whose bioavailability is reportedly 10%-25% compared with the parenteral forms, cannot maintain a long-acting blood concentration. A lot of researches focusing on the structural modification of sCT, adding delivery carrier and absorption-promoting agent have achieved some effects. This article summarized resent studies on the delivery system of sCT.